Iterum Therapeutics PLC
NASDAQ:ITRM

Watchlist Manager
Iterum Therapeutics PLC Logo
Iterum Therapeutics PLC
NASDAQ:ITRM
Watchlist
Price: 1.04 USD 1.96% Market Closed
Market Cap: 41.6m USD

Relative Value

ITRM doesn't have a meaningful market cap.

There is not enough data to reliably calculate the relative value of ITRM.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ITRM Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.5
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-2.1
Industry
21.5
Forward
-0.9
vs History
vs Industry
Median 3Y
-2
Median 5Y
-3.2
Industry
16.6
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-2.8
Industry
24.9
vs History
vs Industry
11
Median 3Y
1.2
Median 5Y
1.6
Industry
2.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.7
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
vs History
vs Industry
56
Median 3Y
-1.2
Median 5Y
-3.7
Industry
12.8
vs History
vs Industry
53
Median 3Y
-1.2
Median 5Y
-3.5
Industry
16.3
Forward
-2.9
vs History
vs Industry
56
Median 3Y
-1.3
Median 5Y
-3.5
Industry
14.9
vs History
vs Industry
44
Median 3Y
-1.3
Median 5Y
-3.5
Industry
17.9
vs History
76
vs Industry
29
Median 3Y
4.5
Median 5Y
12.2
Industry
1.9

Multiples Across Competitors

ITRM Competitors Multiples
Iterum Therapeutics PLC Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
IE
Iterum Therapeutics PLC
NASDAQ:ITRM
41.2m USD 0 -1.8 -3.9 -3.7
US
Eli Lilly and Co
NYSE:LLY
765.3B USD 15.6 68.9 37 40.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
372.8B USD 4.2 17.1 12.5 16.4
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 7.6 21.9 15.1 17.4
CH
Roche Holding AG
SIX:ROG
214.7B CHF 3.5 25.9 9.7 11.4
CH
Novartis AG
SIX:NOVN
190B CHF 4.3 18 10.6 14.2
UK
AstraZeneca PLC
LSE:AZN
169.1B GBP 4.2 29.4 131.2 197.9
US
Merck & Co Inc
NYSE:MRK
201.6B USD 3.2 11.6 8.6 10.4
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
139.2B USD 2.2 17.7 7.6 10.6
P/E Multiple
Earnings Growth PEG
IE
Iterum Therapeutics PLC
NASDAQ:ITRM
Average P/E: 26.3
Negative Multiple: -1.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
68.9
50%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.1
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
21.9
18%
1.2
CH
Roche Holding AG
SIX:ROG
25.9
32%
0.8
CH
Novartis AG
SIX:NOVN
18
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
29.4
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.6
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
17.7
31%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IE
Iterum Therapeutics PLC
NASDAQ:ITRM
Average EV/EBITDA: 434
Negative Multiple: -3.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.2
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.6
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
2%
3.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IE
Iterum Therapeutics PLC
NASDAQ:ITRM
Average EV/EBIT: 1 867.6
Negative Multiple: -3.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.4
32%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
17.4
14%
1.2
CH
Roche Holding AG
SIX:ROG
11.4
6%
1.9
CH
Novartis AG
SIX:NOVN
14.2
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.9
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.4
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.6
10%
1.1